Fresenius SE & Co. KGaA is a diversified healthcare enterprise delivering a broad spectrum of products and services across multiple sectors, including dialysis, hospital operations, and outpatient medical treatment. Its operations are structured into four main divisions: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. Fresenius Medical Care specializes in supporting individuals suffering from chronic kidney disease, supplying essential products like dialyzers, hemodialysis equipment, and associated disposable items, alongside comprehensive dialysis services. Fresenius Kabi focuses on the therapeutic management and care of acutely and chronically ill patients. Its portfolio encompasses a wide range of offerings, including intravenous generic pharmaceuticals for areas like oncology, pain management, anesthesia, infection control, and critical care. It also provides parenteral and enteral nutritional solutions, infusion fluids, blood volume expanders, and biosimilar drugs targeting autoimmune and oncological conditions. Furthermore, the segment supplies medical devices and consumables vital for administering IV medications, infusion therapies, and clinical nutrition, along with transfusion products for blood component collection and various bodily treatments. Fresenius Helios manages a substantial network of healthcare facilities. In Germany, it operates 90 hospitals, around 130 outpatient clinics, and six prevention centers. Its Spanish presence includes 49 hospitals, 88 outpatient clinics, and approximately 300 risk prevention centers. Additionally, this segment extends its services to fertility treatment, operating 33 dedicated clinics and 39 supplementary locations spanning ten countries across three continents. Fresenius Vamed is dedicated to project management and service provision for hospitals and other healthcare infrastructure. Its comprehensive offerings range from project conception, detailed planning, and complete turnkey construction to ongoing maintenance, technical oversight, and operational administration. Originally established in 1912, the company was previously known as Fresenius SE before adopting its current name, Fresenius SE & Co. KGaA, in January 2011. Its global headquarters are situated in Bad Homburg vor der Höhe, Germany.
The current price of FSNUF is $57.00 USD — it has increased by +4.88% in the past 24 hours. Watch Fresenius stock price performance more closely on the chart.
What is Fresenius stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Fresenius stocks are traded under the ticker FSNUF.
Is Fresenius stock price growing?▼
FSNUF stock has risen by +4.88% compared to the previous week, the month change is a +0% rise, over the last year Fresenius has showed a +23.35% increase.
What is Fresenius market cap?▼
Today Fresenius has the market capitalization of 32.1B
When is the next Fresenius earnings date?▼
Fresenius is going to release the next earnings report on August 05, 2026.
What were Fresenius earnings last quarter?▼
FSNUF earnings for the last quarter are 0.95 USD per share, whereas the estimation was 1.01 USD resulting in a -6.29% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Fresenius revenue for the last year?▼
Fresenius revenue for the last year amounts to 26.35B USD.
What is Fresenius net income for the last year?▼
FSNUF net income for the last year is 1.44B USD.
Does Fresenius pay dividends?▼
Yes, FSNUF dividends are paid annual. The last dividend per share was 1.22 USD. As of today, Dividend Yield (FWD)% is 2.14%.
How many employees does Fresenius have?▼
As of July 20, 2026, the company has 175,202 employees.
In which sector is Fresenius located?▼
Fresenius operates in the Health & Wellness sector.
When did Fresenius complete a stock split?▼
The last stock split for Fresenius was on August 05, 2014 with a ratio of 1.5:1.
Where is Fresenius headquartered?▼
Fresenius is headquartered in Bad Homburg vor der Höhe, Germany.